about
Next-generation prognostic assessment for diffuse large B-cell lymphomaNext-generation surveillance strategies for patients with lymphomaLenalidomide for the treatment of B-cell lymphoma.Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialPIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro.Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cellsOutcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.The future of kinase inhibitors for DLBCL?
P2860
Q26796428-0BCC0946-55DA-4B3F-BA5E-617CC9704150Q28084956-27C1FB64-8484-45C2-9E96-61B94E3AA403Q30249007-3DAF38C1-1BB6-4337-A883-DC6676D79F00Q33431267-165AF04E-79CD-4D75-98CA-4C86517546ACQ33602560-2E88B17D-DC27-476C-8EA5-A622D51E2338Q33808800-8125D8D8-1F90-4EC8-A79E-1598B6AA19A8Q48792987-B7F08319-4788-427B-9585-C8E06C720F1EQ54978376-69CBA2B1-B9BC-4D60-AD64-4358763B769D
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Emerging drugs for diffuse large B-cell lymphoma.
@en
type
label
Emerging drugs for diffuse large B-cell lymphoma.
@en
prefLabel
Emerging drugs for diffuse large B-cell lymphoma.
@en
P2860
P1476
Emerging drugs for diffuse large B-cell lymphoma.
@en
P2093
Anas Younes
P2860
P304
P356
10.1586/14737140.2015.1009042
P50
P577
2015-02-05T00:00:00Z